A systematic review of the antipsychotic properties of cannabidiol in humans

Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice

Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628

Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality

McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224

Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study

Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159

The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 ‐tetrahydrocannabinol, cannabidiol and Δ 9 ‐tetrahydrocannabivarin

Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 2,047

Schizophrenia

van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971

Endocannabinoid-Mediated Control of Synaptic Transmission

Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315

Schizophrenia, “just the facts” 4. Clinical features and conceptualization

Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,101

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059

A review of the industrial use and global sustainability of Cannabis sativa

Raihan, A., & Bijoy, T. R. (2023) · Global Sustainability Research · doi:10.56556/gssr.v2i4.597 · Cited by 39

Early life stress and development of the endocannabinoid system: A bidirectional process in programming future coping

Ferber, S. G., Trezza, V., & Weller, A. (2019) · Developmental Psychobiology · doi:10.1002/dev.21944 · Cited by 38

The potential role of cannabinoids in epilepsy treatment

Caro, C. D., Leo, A., Citraro, R., Sarro, C. D., Russo, R., Calignano, A., & Russo, E. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1373019 · Cited by 36

Could cannabidiol be used as an alternative to antipsychotics?

Fakhoury, M. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.05.013 · Cited by 33

Fast electroanalytical determination of Cannabidiol and Cannabinol in aqueous solution using Sonogel-Carbon-PEDOT devices

López-Iglesias, D., García‐Guzmán, J. J., Zanardi, C., Santander, J. M. P., Aguilera, L. C., & Pigani, L. (2020) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2020.114591 · Cited by 31

Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility

Aguilar, D. D., Giuffrida, A., & Lodge, D. J. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy003 · Cited by 31

Endocannabinoid and dopaminergic system: the pas de deux underlying human motivation and behaviors

Laksmidewi, A. A. A. P., & Soejitno, A. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02326-y · Cited by 35

TAXING THE POTENCY OF SIN GOODS

Hansen, B., Miller, K. S., Seo, B., & Weber, C. E. (2020) · National Tax Journal · doi:10.17310/ntj.2020.2.07 · Cited by 30

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment

Woerdenbag, H. J., Olinga, P., Kok, E. A., Brugman, D. A. P., van Ark, U. F., Ramcharan, A. S., Lebbink, P. W., Hoogwater, F. J. H., Knapen, D. G., de Groot, D. J. A., et al. (2023) · Cancers · doi:10.3390/cancers15072119 · Cited by 30

Current Understanding of the Neurobiology of Agitation

Miller, C. W. T., Hodzic, V., & Weintraub, E. (2020) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2020.4.45779 · Cited by 31

Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning

Sánchez‐Gutiérrez, T., Fernández‐Castilla, B., Barbeito, S., González-Pinto, A. M., Becerra‐García, J. A., & Calvo, A. (2020) · European Psychiatry · doi:10.1192/j.eurpsy.2019.9 · Cited by 28

Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles

Fedorova, E. V., Wong, C. F., Ataiants, J., Iverson, E., Conn, B. M., & Lankenau, S. E. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108648 · Cited by 28

The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines

Müller, L., Radtke, A., Decker, J., Koch, M., & Belge, G. (2017) · Anticancer Research · doi:10.21873/anticanres.12086 · Cited by 27

Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?

Loss, C. M., Teodoro, L., Rodrigues, G. D., Moreira, L. R., Peres, F. F., Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., & Abílio, V. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.635763 · Cited by 27

A narrative review of the ethnomedicinal usage of Cannabis sativa Linnaeus as traditional phytomedicine by folk medicine practitioners of Bangladesh

Shakil, S. S. M., Gowan, M., Hughes, K., Azam, M. N. K., & Ahmed, M. N. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00063-3 · Cited by 27

A Novel Tetrahydrocannabinol Electrochemical Nano Immunosensor Based on Horseradish Peroxidase and Double-Layer Gold Nanoparticles

Lu, D., Lu, F., & Pang, G. (2016) · Molecules · doi:10.3390/molecules21101377 · Cited by 26

Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders

Thomsen, K. R., Thylstrup, B., Pedersen, M. M., Pedersen, M. U., Simonsen, E. H., & Hesse, M. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.09.026 · Cited by 25

Recommendation to reconsider examining cannabis subtypes together due to opposing effects on brain, cognition and behavior.

Rømer Thomsen, K., Callesen, M. B., & Feldstein Ewing, S. W. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.025 · Cited by 24

Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum

Pedrazzi, J. F. C., Sales, A. J., Guimarães, F. S., Joca, S. R. L., Crippa, J. A., & Bel, E. A. D. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110352 · Cited by 23

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study

Chester, L. A., Englund, A., Chesney, E., Oliver, D., Wilson, J., Sovi, S., Dickens, A. M., Orešič, M., Linderman, T., Hodsoll, J. P., et al. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0174 · Cited by 24

Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ 9 ‐Tetrahydrocannabinol Without Improving Its Analgesic Properties

Gorbenko, A. A., Heuberger, J. A. A. C., Klumpers, L. E., de Kam, M. L., Strugala, P. K., de Visser, S. J., & Groeneveld, G. J. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3381 · Cited by 24

Preliminary Evaluation of the Use of a Disposable Electrochemical Sensor for Selective Identification of Δ9-Tetrahydrocannabinol and Cannabidiol by Multivariate Analysis

Zanfrognini, B., Monari, A., Foca, G., Ulrici, A., Pigani, L., & Zanardi, C. (2022) · Microchemical Journal · doi:10.1016/j.microc.2022.108108 · Cited by 23

Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis

Theunissen, E. L., Reckweg, J. T., Hutten, N. R. P. W., Kuypers, K. P. C., Toennes, S. W., Neukamm, M. A., Halter, S., & Ramaekers, J. G. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05768-0 · Cited by 21

Autism and associated disorders: cannabis as a potential therapy

Babayeva, M., Assefa, H., Basu, P., & Loewy, Z. G. (2022) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1401001 · Cited by 27

From Cannabinoids and Neurosteroids to Statins and the Ketogenic Diet: New Therapeutic Avenues in Rett Syndrome?

Mouro, F. M., Miranda‐Lourenço, C., Sebastião, A. M., & Diógenes, M. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00680 · Cited by 22

Cannabidiol attenuated the maintenance and reinstatement of extinguished methylphenidate-induced conditioned place preference in rats

Kashefi, A., Tomaz, C. A. B., Jamali, S., Rashidy‐Pour, A., Vafaei, A. A., & Haghparast, A. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.11.021 · Cited by 21

Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors

Yang, Y., Vyawahare, R., Lewis‐Bakker, M. M., Clarke, H. A., Wong, A. H. C., & Kotra, L. P. (2020) · Molecules · doi:10.3390/molecules25153466 · Cited by 18

Effects of cannabinoids on the development of chick embryos in ovo

Gustafsson, S. B., & Jacobsson, S. O. P. (2019) · Scientific Reports · doi:10.1038/s41598-019-50004-7 · Cited by 20

Impact of O-H···π Hydrogen Bond on IR and NMR Parameters of Cannabidiol: Theoretical and Experimental Study

Buczek, A., Rzepiela, K., Kupka, T., & Broda, M. A. (2025) · Molecules · doi:10.3390/molecules30122591 · Cited by 17

Patterns and correlates of cannabidiol product and marijuana co-use in a sample of U.S. young adults

Dunbar, M. S., Seelam, R., Tucker, J. S., Firth, C. L., Pedersen, E. R., Klein, D. J., Rodriguez, A., & D’Amico, E. J. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.107185 · Cited by 16

Anandamide Hydrolysis Inhibition Reverses the Long-Term Behavioral and Gene Expression Alterations Induced by MK-801 in Male Rats: Differential CB1 and CB2 Receptor-Mediated Effects

Bauminger, H., Zaidan, H., Akirav, I., & Gaisler‐Salomon, I. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab153 · Cited by 16

Assessment and treatment of individuals at high risk for psychosis

Andreou, C., Bailey, B. K., & Borgwardt, S. (2019) · BJPsych Advances · doi:10.1192/bja.2019.3 · Cited by 15

Impact of conformational and solubility properties on psycho-activity of cannabidiol (CBD) and tetrahydrocannabinol (THC)

Bragança, V. A. N., de França, T. G., de Jesus, A. C. S. P. S., Palheta, I. C., Melo, F. P. A., das Neves, P. A. P. F. G., Lima, A. H., & Borges, R. S. (2020) · Chemical Data Collections · doi:10.1016/j.cdc.2020.100345 · Cited by 15

Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review

Cammà, G., Verdouw, M. P., van der Meer, P. B., Groenink, L., & Batalla, A. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.10.006 · Cited by 16

What are the informational pathways that shape people’s use of cannabidiol for medical purposes?

Zenone, M. A., Snyder, J., & Crooks, V. A. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00069-x · Cited by 15

Cannabidiol for at risk for psychosis youth: A randomized controlled trial

Amminger, G. P., Lin, A. P., Kerr, M., Weller, A., Spark, J., Pugh, C., O’Callaghan, S., Berger, M., Clark, S. R., Scott, J. G., et al. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13182 · Cited by 17

Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?

Thomsen, K. R., Thylstrup, B., Kenyon, E. A., Lees, R., Baandrup, L., Ewing, S. W. F., & Freeman, T. P. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.033 · Cited by 15

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia

van Amsterdam, J., Vervloet, J., Oene, G. H. D. W.-V., Buwalda, V. J. A., Goudriaan, A. E., & van den Brink, W. (2018) · Harm Reduction Journal · doi:10.1186/s12954-018-0253-7 · Cited by 14

Evaluation of Industrial Hemp Seed Treatments for Management of Damping-Off for Enhanced Stand Establishment

Mayton, H. S., Amirkhani, M., Loos, M., Johnson, B. L., Fike, J. H., Johnson, C. S., Myers, K., Starr, J., Bergstrom, G. C., & Taylor, A. G. (2022) · Agriculture · doi:10.3390/agriculture12050591 · Cited by 14

Enhancing transmucosal delivery of CBD through nanoemulsion: in vitro and in vivo studies

Provenzano, R., Caro, C. D., Vitiello, A., Izzo, L., Ritieni, A., Ungaro, F., Quaglia, F., Russo, E., Miro, A., & d’Angelo, I. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01481-x · Cited by 15

Oxylipin biosynthetic gene families of Cannabis sativa

Borrego, E. J., Robertson, M., Taylor, J. T., Schultzhaus, Z. S., & Espinoza, E. M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0272893 · Cited by 13

Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review

Bartoli, F., Riboldi, I., Bachi, B., Calabrese, A., Moretti, F., Crocamo, C., & Carrà, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061303 · Cited by 16

Factors influencing the in situ formation of Δ9‐THC from cannabidiol during GC–MS analysis

Cheng, Y., & Kerrigan, S. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3617 · Cited by 13

Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report

Ricci, V., Martinotti, G., Berardis, D. D., & Maina, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192316057 · Cited by 13

Clinical Management of Sleep and Sleep Disorders With Cannabis and Cannabinoids: Implications to Practicing Psychiatrists

Monti, J. M., & Pandi-Perumal, S. R. (2022) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000494 · Cited by 12

Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials

Müller, A. R., den Hollander, B., van de Ven, P. M., Roes, K. C. B., Geertjens, L., Bruining, H., van Karnebeek, C., Jansen, F. E., de Wit, M. Y., ten Hoopen, L. W., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-023-05422-3 · Cited by 12

Investigating Cannabidiol's potential as a supplementary treatment for schizophrenia: A narrative review

Völker, J. S. D., Micluția, I., & Vinași, R.-C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176821 · Cited by 14

Interaction of sex and cannabis in adult in vivo brain imaging studies: A systematic review

Francis, A. M., Bissonnette, J. N., MacNeil, S. E., Crocker, C. E., Tibbo, P. G., & Fisher, D. J. (2022) · Brain and Neuroscience Advances · doi:10.1177/23982128211073431 · Cited by 10

Interactions between cannabis and schizophrenia in humans and rodents

Moustafa, A. A., Salama, M., peak, R., Tindle, R., Salem, A., Kéri, S., Misiak, B., Frydecka, D., & Mohamed, W. M. Y. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0083 · Cited by 13

The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study

Sainz-Cort, A., Jiménez-Garrido, D. F., Marrón, E. M., Viejo-Sobera, R., Heeroma, J. H., & Bouso, J. C. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0037 · Cited by 10

Exploring Interventions for Sleep Disorders in Adolescent Cannabis Users

Furer, T., Nayak, K., & Shatkin, J. P. (2018) · Medical Sciences · doi:10.3390/medsci6010011 · Cited by 10

The Association Between Cannabinoids and Psychosis

Tikka, S. K., & D’Souza, D. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-90365-1_14 · Cited by 10

Clinical/Therapeutic Approaches for Cannabinoid Ligands in Central and Peripheral Nervous System Diseases

Fijał, K., & Filip, M. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000132 · Cited by 10

The Endocannabinoid System in Prefrontal Synaptopathies

Scheyer, A. F., Martin, H. G. S., & Manzoni, O. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-57371-7_7 · Cited by 10

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study

Köck, P., Lang, E., Trulley, V.-N., Dechent, F., Mercer‐Chalmers‐Bender, K., Frei, P., Huber, C. G., & Borgwardt, S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.736822 · Cited by 9

Effects of persistent cannabis use on depression, psychosis, and suicidality following cannabis‐induced psychosis: A longitudinal study

Ricci, V., Berardis, D. D., Martinotti, G., & Maina, G. (2025) · American Journal on Addictions · doi:10.1111/ajad.70048 · Cited by 9

ABCB1 1199G > A Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics

Wang, R., Sun, X., Deng, Y.-S., & Qiu, X.-W. (2018) · DNA and Cell Biology · doi:10.1089/dna.2017.4096 · Cited by 9

Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity

Chetia, S., & Borah, G. (2020) · Natural Products and Bioprospecting · doi:10.1007/s13659-020-00263-z · Cited by 9

Determination of cannabinoids in hair: Indicators for illegal vs CBD-rich cannabis use

Casati, S., Angeli, I., Bergamaschi, R. F., Ravelli, A., Colombo, G., Binelli, G., Minoli, M., & Orioli, M. (2022) · Forensic Science International · doi:10.1016/j.forsciint.2022.111237 · Cited by 9

The Construct of Medical and Non-Medical Marijuana—Critical Review

Silczuk, A., Smułek, D., Kołodziej, M., & Gujska, J. H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19052769 · Cited by 9

CANNABIS USE AND SUICIDE IN NON-AFFECTIVE PSYCHOSIS: A MINI-REVIEW OF RECENT LITERATURE

Ricci, V., Cristofori, E., Passarello, E., Paggi, A., Cavallo, A., Ceci, F., Martinotti, G., Berardis, D. D., & Maina, G. (2023) · Psychiatria Danubina · doi:10.24869/psyd.2023.307 · Cited by 8

Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial

Parrella, N.-F., Hill, A. T., Enticott, P. G., Botha, T., Catchlove, S. J., Downey, L. A., & Ford, T. C. (2025) · Autism Research · doi:10.1002/aur.70159 · Cited by 9

A Comparison of Acute Neurocognitive and Psychotomimetic Effects of a Synthetic Cannabinoid and Natural Cannabis at Psychotropic Dose Equivalence

Theunissen, E. L., Kuypers, K. P. C., Mason, N. L., & Ramaekers, J. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.891811 · Cited by 8

Cannabis-Induced Psychotic Disorders

Pauselli, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804791-0.00008-2 · Cited by 8

Assessing Cannabis Use Disorder in Medical Cannabis Patients: Interim Analyses from an Observational, Longitudinal Study

Sagar, K. A., Dahlgren, M. K., Smith, R. T., Lambros, A. M., & Gruber, S. A. (2021) · Cannabis · doi:10.26828/cannabis/2021.02.004 · Cited by 7

Cannabidiol (CBD) modulates the transcriptional profile of ethanol-exposed human dermal fibroblast cells

Gurgul, A., Żurowski, J., Szmatoła, T., Kucharski, M., Sawicki, S., Semik‐Gurgul, E., & Oclon, E. A. (2024) · Journal of Applied Genetics · doi:10.1007/s13353-024-00915-7 · Cited by 7

The Neuroprotective Properties, Functions, and Roles of Cannabis sativa in Selected Diseases Related to the Nervous System

Mahdi, O., Baharuldin, M. T. H., Nor, N. H. M., Chiroma, S. M., Jagadeesan, S., & Moklas, M. A. M. (2021) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524921666210127110028 · Cited by 6

The Contribution of Studies with Canabidiol and Synthetic Analogues in the Design of New Drug Candidates for Neuropsychiatric Disorders and Neurodegenerative Diseases

Franco, G. R. R., & Viegas, C. (2017) · Revista Virtual de Química · doi:10.21577/1984-6835.20170103 · Cited by 7

Cannabinoid-Based Drugs: Potential Applications in Addiction and Other Mental Disorders

Don, W., & Piomelli, D. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150009 · Cited by 7

Water modulated influence of intramolecular hydrogen-bonding on the conformational properties of Cannabidiol (CBD)

Buczek, A., Rzepiela, K., Broda, M. A., Kupka, T., Strodel, B., & Fatafta, H. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.127033 · Cited by 6

Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder

Al‐Soleiti, M., Balaj, K., Thom, R. P., McDougle, C. J., & Keary, C. J. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05254-8 · Cited by 7

Is cannabidiol an effective treatment for schizophrenia?

Guinguis, R., Ruiz, M. I., & Gabriel Rada, G. (2017) · Medwave · doi:10.5867/medwave.2017.07.7010 · Cited by 6

Cannabis sativa essential oils orally administered to CD1 mice: Tissue distribution of main constituents

Sut, S., Mazzara, E., Maggi, F., Castagliuolo, I., Dall’Acqua, S., & Petrelli, R. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106147 · Cited by 5

The impact of cannabis use on ageing and longevity: a systematic review of research insights

Nain, S., Singh, N., Schlag, A. K., & Barnes, M. (2025) · Journal of Cannabis Research · doi:10.1186/s42238-025-00267-x · Cited by 7

Putative effects of cannabidiol in depression and synaptic plasticity

Joca, S. R. L., Silote, G. P., Sartim, A. G., Sales, A. J., Guimarães, F. S., & Wegener, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00052-9 · Cited by 5

Psychiatric Hospitalization and Length of Stay Differences in Cannabis Users and Non-Users with a Primary Discharge Diagnosis of Schizophrenia or Schizoaffective Disorder

Williams, S. R., Agapoff, J. R., Jalan, D., Hishinuma, E. S., & Kida, L. E. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1949615 · Cited by 5

Cannabis und Schadensminderung in Deutschland

Manthey, J., Stöver, H., & Meyer-Thompson, H.-G. (2017) · Suchttherapie · doi:10.1055/s-0043-112067 · Cited by 5

The comparison of violence, and the relationship with childhood trauma in Turkish men with alcohol, opiate, and synthetic cannabinoid use disorder

Ergelen, M., Yalçın, M., & Bilici, R. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s173604 · Cited by 5

Medical cannabis and cannabidiol: A new harvest for Malawi

Bandawe, G. P. (2022) · Malawi Medical Journal · doi:10.4314/mmj.v34i2.10 · Cited by 5

Where Are We and Where Are We Going?

Iversen, L. L. (2018) · Oxford University Press eBooks · doi:10.1093/oso/9780190846848.003.0008 · Cited by 5

CBD’s potential impact on Parkinson’s disease: An updated overview

Ghachi, H. E., Soulimani, R., Gamrani, H., & Kissani, N. (2024) · Open Medicine · doi:10.1515/med-2024-1075 · Cited by 7

A Systematic Review of Cannabis and Anxiety: Chicken or Egg?

Blyth, L. G., Seal, C., Sorkhou, M., Lowe, D. J. E., & George, T. P. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00650-x · Cited by 4

Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors

Goulette, M. R., Schlienz, N. J., Case, A. A., Hansen, E., Rivard, C., Ashare, R. L., Goniewicz, M. L., Bansal‐Travers, M., Hyland, A. J., & Smith, D. M. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08374-w · Cited by 4

Nanoemulsion Improves Antinociceptive Activity of HP1, a Benzopyran from Hypericum polyanthemum

Meirelles, G. D. C., Bridi, H., Stolz, E. D., Teixeira, H. F., von Poser, G. L., & Rates, S. M. K. (2017) · Planta Medica International Open · doi:10.1055/s-0043-119759 · Cited by 4

Effect of cannabidiol on schizophrenia based on randomized controlled trials: A meta-analysis

Zhang, S., Li, M., & Guo, Z. (2021) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2021.09.019 · Cited by 5

Liprin alfa 2 gene expression is increased by cannabis use and associated with neuropsychological function

He, Y., de Witte, L. D., Schubart, C. D., van Gastel, W. A., Koeleman, B. P. C., de Jong, S., Ophoff, R. A., Hol, E. M., & Boks, M. P. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.03.004 · Cited by 4

The effects of standardized cannabis products in healthy volunteers and patients: a systematic literature review

Leen, N. A., Kowal, M. A., Batalla, A., & Bossong, M. G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1411631 · Cited by 3

Cannabidiol reverses myeloperoxidase hyperactivity in the prefrontal cortex and striatum, and reduces protein carbonyls in the hippocampus in a ketamine-induced schizophrenia rat model

Queiroz, S. D. A., Júnior, L. R. D. N., de Carvalho, A. B. P., da Silva, T. V., Ramos, S. D. S., Meneguzzo, V., Mathias, K., Tiscoski, A. D. B., Piacentini, N., Goldim, M. P. D. S., et al. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.03.031 · Cited by 3

Negative effect of cannabinoids on the course of paranoid schizophrenia

Klimova, I. Y., & Овчинников, А. А. (2019) · JOURNAL of SIBERIAN MEDICAL SCIENCES · doi:10.31549/2542-1174-2019-2-79-84 · Cited by 3

Detecting Tweets Containing Cannabidiol-Related COVID-19 Misinformation Using Transformer Language Models and Warning Letters From Food and Drug Administration: Content Analysis and Identification

Turner, J., Kantardzic, M. M., Vickers‐Smith, R., & Brown, A. G. (2022) · JMIR Infodemiology · doi:10.2196/38390 · Cited by 3

Characterizing the Use of Nabiximols (∆9-Tetrahydrocannabinol–Cannabidiol) Buccal Spray in Pediatric Patients

Hagg, L., Leung, S., & Carr, R. R. (2023) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.3349 · Cited by 3

IUPHAR review: Drug repurposing in Schizophrenia – An updated review of clinical trials

Zaki, J. K., Tomasik, J., & Bahn, S. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107633 · Cited by 3

Le cannabis et ses effets délétères : pour un débat plus nuancé

Jobidon, L., & Jutras‐Aswad, D. (2018) · Drogues santé et société · doi:10.7202/1044306ar · Cited by 3

Cannabis und Schizophrenie – Risikofaktoren, diagnostische Einordnung und Auswirkungen auf Verlauf und Prognose

Roser, P. (2019) · Forensische Psychiatrie Psychologie Kriminologie · doi:10.1007/s11757-019-00543-6 · Cited by 3

Cannabis Use and Mental Health: Paradoxes of Medicalization

Dolphin, W., & Newhart, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-83745-7_11 · Cited by 3

Clinical predictors of mortality in dual diagnosis patients receiving integrated in‐patient treatment—A cohort study with 21 years follow‐up

Düring, S. W., Jobe, L. B., Balleby, M. R., & Mårtensson, S. (2025) · Addiction · doi:10.1111/add.70125 · Cited by 2

Antimicrobial properties of secondary metabolites of Cannabis sativa: A promising natural alternative for livestock health

Paulová, T., Novák, K., & Pěchoučková, E. (2025) · Czech Journal of Animal Science · doi:10.17221/85/2025-cjas · Cited by 2

The role of cannabinoids in the management of symptoms in palliative care patients

Graczyk, M., & Leppert, W. (2021) · Palliative Medicine in Practice · doi:10.5603/pmpi.2021.0016 · Cited by 3

Exploring medicinal use of low-THC cannabis products - Comparing experienced effects and side-effects between CBD-oil-only users to users of high-THC cannabis products

Kvamme, S. L., Pedersen, M. M., Thomsen, K. R., & Thylstrup, B. (2024) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2024.2311188 · Cited by 2

New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report

Alhassan, A., Prahad, S. R., Burk, B. G., Fargason, R. E., & Birur, B. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4481 · Cited by 2

Cannabidiolɗs Role as a Potential Target in the Treatment for Schizophrenia

Carvalho, A. C., Felgueiras, J., Abreu, T., Freitas, C., & Silva, J. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.01.1028

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation

Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222

Cannabidiol: An Overview of its Antipsychotic Properties

Peres, F. F., de Almeida, V., & Abílio, V. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00092-2 · Cited by 1

Cannabidiol as a Potential Novel Therapeutic Agent for Psychotic Disorders

Deiana, S., & Zamberletti, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804791-0.00014-8 · Cited by 1

Cannabidiol as an antipsychotic drug

Fabris, D., Lisboa, J. R., Guimarães, F. S., & Gomes, F. V. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.04.013 · Cited by 7